Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
An Open, Single-center, Stage I Clinical Study of Individualized Tumor Specific TCR-T Cells in the Treatment of Advanced Solid Tumors.
The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor .
The secondary purpose of this study is to preliminarily showed the effect of TCR-T cells in the treatment of advanced Solid Tumor .
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Xuzhi Pan
- Phone Number: 86-20-87343135
- Email: panxzh@sysucc.org.cn
Study Contact Backup
- Name: Haiping Liu
- Phone Number: 020-31605836
- Email: liuhp11@fineimmu.com
Study Locations
-
-
gaungdong
-
Guangzhou, gaungdong, China, 510700
- Recruiting
- Sun Yat-sen University Cancer Center
-
Contact:
- Xuzhi Pan
- Phone Number: 86-20-87343135
- Email: panxzh@sysucc.org.cn
-
Contact:
- Xiaoshi Zhang, professor
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged between 18 and 70 years old, regardless of gender;
- Diagnosed as solid tumors by histopathology, and the tumor lesions could be detected or evaluated;
- Be after standard treatment or who lack effective treatment programs;
- Patients and their families were willing to participate in the clinical trial and signed the informed consent;
- Physical status: ECOG score 0-1;
- Expected survival time > 3 months;
- HIV antibody negative;Hepatitis b surface antigen negative;Hepatitis c antibody negative;The results of blood routine and coagulation were roughly normal, lymphocyte >0.8×10^9/L, hemoglobin >100g/L, and the pregnancy test of female patients with fertility potential was negative.
- Left ventricular ejection fraction 50% as indicated by cardiac ultrasound;Upper normal level of serum ALT/AST < 2.5 times;Serum creatinine 1.6mg/dl;Total bilirubin 1.5mg/dl, subject's total bilirubin < 3mg/dl except for Gilberts Syndrome;
- At least 4 weeks after the last systemic treatment, the patient's toxic and side effects must be restored to grade 1 or lower (except for alopecia or vitiligo).If the subject undergoes minor surgery within 3 weeks prior to enrollment, as long as all toxicity is recovered to level 1 or lower, the subject will meet the enrollment requirements.
- During the whole study period, patients can regularly visit the enrolled research institutions for relevant detection, evaluation and management;
- The patient is not allowed to use any anti-tumor drugs or treatments for 4 weeks prior to the infusion of TCR-T cells;
- Patients' tumor lesions can be obtained by surgery or puncture, and tumor infiltrating T cells can be successfully isolated from the obtained tumor tissue;
- T cells in patients' peripheral blood can effectively proliferate and expand by at least 10 times in the Pre-culture;
- The benefits of participating in the clinical trial outweigh the risks,which was evaluated by the researchers base on the status or condition of the patients.
Exclusion Criteria:
- Any form of primary immunodeficiency disease (such as severe combined immunodeficiency disease);
- Experiencing moderate to severe infection or possible opportunistic infection;
- Patients with a history of autoimmunity (e.g., SLE, psoriasis, etc.);
- Acute systemic infection, coagulation dysfunction or other serious cardiopulmonary diseases;
- Patients who have is suffering a large amount of glucocorticoid or other immunosuppressive agents within 4 weeks;
- Be allergic to any drug used in this study;
- Central nervous system metastases patients with clinically unstable or acute meningitis (except these clinically stable after treatment) Clinical stability needs to be met as follows: 4 weeks at least before the trial treatment, 1) no new brain lesion or no expanded of the original lesions confirmed by MRI); 2) no hormone therapy for at least 2 weeks; 3) neurological symptoms have returned to baseline;
- Pregnant and lactating women, as well as male and female patients who could not cooperate with contraception during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TCR-T cell infusion
Patient will exposed to Individualized Tumor-t Cell Receptor (TCR) -Mediated T Cells therapy
|
On day 0 and day 14, 0.5-5x10^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.
Other Names:
Aldesleukin 3,000,000 IU.
IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
Time Frame: At least 45 days
|
Keep records the adverse events experienced by subjects in 30 days after the last infusion.
|
At least 45 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease Control Rate(DCR)
Time Frame: one year
|
DCR is defined as the proportion of patients with tumor size reduction(CR,PR) and stable (SD) assessed by RECIST 1.1 and iRECIST
|
one year
|
|
overall survival(OS)
Time Frame: two year
|
The time from the first injection of Investigational Product until death
|
two year
|
|
progression-free survival(PFS)
Time Frame: two year
|
PFS is defined as the time from the first injection of Investigational Product until objective tumor progression or death, whichever occurs first.Assessed by RECIST 1.1 and iRECIST
|
two year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Penghui Zhou, Guangzhou FineImmune Biotechnology Co., LTD.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FI-FIT001-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.